{"id":135629,"date":"2024-05-03T14:45:38","date_gmt":"2024-05-03T18:45:38","guid":{"rendered":"https:\/\/ccs.ca\/?page_id=135629"},"modified":"2024-05-21T14:10:10","modified_gmt":"2024-05-21T18:10:10","slug":"2024-ccs-bms-hypertrophic-cardiomyopathy-hcm-research-award","status":"publish","type":"page","link":"https:\/\/ccs.ca\/2024-ccs-bms-hypertrophic-cardiomyopathy-hcm-research-award\/","title":{"rendered":"2024 CCS-BMS HYPERTROPHIC CARDIOMYOPATHY (HCM) RESEARCH AWARD – Handbook"},"content":{"rendered":"\n
The CCS Research Fellowships and Awards program was established to foster growth of peer-reviewed Canadian cardiovascular research and researchers. With support from like-minded organizations committed to empowering clinician scientists nationally, the CCS Research Fellowships and Awards program supports topics of research that span the various areas of cardiovascular medicine. The CCS, and all program partners, encourage all eligible CCS members to apply including underrepresented groups women and gender minorities, Indigenous Peoples, persons with disabilities, racialized individuals, and members of the 2SLGBTQIA+ communities.<\/p>\n\n\n\n
Please refer to Appendix A for CCS Terms and Conditions for all CCS Research and Fellowship Awards<\/a><\/p>\n\n\n\n For information regarding research programs, governing policies, and application submissions, please contact: Research and Fellowship Awards Email: researchawards@ccs.ca<\/a><\/p>\n\n\n\n Application submissions must be made online through the CCS On-line submission platform<\/a>. CCS offers a secure internet portal which allows the applicant to electronically submit grant applications. All application submissions are due online on Cadmium by May 7, 2024. Additional time allowances will not usually be granted for any reason. Notices of Decision will be shared in mid-July 2024. Funding is projected to be disbursed starting in fall 2024.<\/p>\n\n\n\n The Canadian Cardiovascular Society and Bristol Myers Squibb (BMS) are proud to support the CCS-BMS Hypertrophic Cardiomyopathy (HCM) Research Award. The purpose of this award is to foster growth of peer-reviewed Canadian research in the area of HCM, with a focus on HCM diagnosis, progression, monitoring, epidemiology and \/ or prevalence.<\/p>\n\n\n\n The objective of the Hypertrophic Cardiomyopathy (HCM) Research Award is:<\/p>\n\n\n\n The principal investigator must be an early career researcher (ECR). An early career researcher (ECR) is a researcher within five years of the date of their first independent research-related appointment at an academic institution. Given that career progress for an ECR is particularly vulnerable to normal life circumstances, CCS will adjust the eligibility window, as per CIHR applications, as follows:<\/p>\n\n\n\n Reports must be submitted by October of the subsequent year. If required an additional final report must be submitted within 6 months of the end date of the research, and a retrospective report is required 5 years after funding is completed.<\/p>\n\n\n\n Two (2) awards of up to $55,000 each will be awarded based on an independent peer review process. A total of $110,000 in funding is available across the two awards.<\/p>\n\n\n\n Award funds will be administered by the Institution of the awardee\u2019s affiliated university or equivalent.<\/p>\n\n\n\n Funding is provided for one (1) year. Depending on the circumstances, a no-cost extension could be available with an additional interim progress report and an explanation for the need for the extension.<\/p>\n\n\n\nCONTACT<\/u><\/strong><\/h2>\n\n\n\n
DEADLINE<\/u><\/strong><\/h2>\n\n\n\n
FUNDING OPPORTUNITY<\/u><\/strong><\/h2>\n\n\n\n
OBJECTIVE<\/span><\/strong><\/h2>\n\n\n\n
\n
ELIGIBILITY CRITERIA<\/u><\/strong><\/h2>\n\n\n\n
\n
\n
\n
ANNUAL\/FINAL REPORTS<\/u><\/strong><\/h2>\n\n\n\n
THE AWARD<\/u><\/strong><\/h2>\n\n\n\n
TERM<\/u><\/strong><\/h2>\n\n\n\n
SUBMITTING YOUR APPLICATION<\/u><\/strong><\/h2>\n\n\n\n